Hims & Hers Continues to Sell Affordable Weight Loss Injections Despite Parting Ways With Novo Nordisk
Reading Time: 3 minutes
Hims & Hers Health will continue its controversial business of providing affordable semaglutide injections despite the surprising exit of Novo Nordisk. Just one day after the partnership collapsed, CEO Andrew Dudum announced that the company would still offer compounded Wegovy alternatives for patients, openly opposing the Danish pharmaceutical company. Novo ended its cooperation with the telemedicine provider on June 23 and raised serious allegations: Hims & Hers was accused of engaging in "misleading marketing" with copies of the Wegovy...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
